Ensysce Biosciences Inc (ENSC) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ENSC Annual Balance Sheets →
This page allows investors to track Ensysce Biosciences Inc's balance sheet development across multiple reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent0.75
Cash & Short-term Investments0.00
Unbilled Receivables, Current RE0.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current1.26
Total Current Assets2.01
Equipment/Property/Plant Net0.12
Other Assets, Noncurrent0.04
Total Assets2.17
Liabilities
Accounts Payable, Current AC1.61
Other Accrued Liabilities, Current0.98
Notes Payable, Current NO0.25
Other Liabilities, Current0.00
Total Current Liabilities2.84
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Total Liabilities2.84
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock142.94
Retained Earnings / Accumulated Deficit-143.28
Other Equity0.00
Common Stockholder's Equity-0.34
Non-controlling interests & other-0.33
Total Stockholder's Equity-0.67
Liabilities & Stockholder's Equity2.17
4 historic quarters locked

Sign in to unlock the full Ensysce Biosciences Inc balance sheet history.

About Ensysce Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-037817

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.